| [1] Ramsland P A,Hutchinson A T,Carter P J.Therapeutic antibodies:Discovery,design and deployment.Mol Immunol,2015,67(2 Pt A):1-3.
[2] Janice M.Antibodies to watch in 2016.MAbs,2016,8(2):197-204.
[3] Ito T,Tsumoto K.Effects of subclass change on the structural stability of chimeric,humanized,and human antibodies under thermal stress.Protein Sci,2013,22(11):1542-1551.
[4] Salfeld J G.Isotype selection in antibody engineering.Nat Biotechnol,2007,25(12):1369-1372.
[5] Jefferis R.Antibody therapeutics:isotype and glycoform selection.Expert Opin.Biol,2007,7(9):1401-1413.
[6] Irani V,Guy A J,Andrew D,et al.Molecular properties of human IgG subclasses and their implicationsfor designing therapeutic monoclonal antibodies against infectious diseases.Mol Immunol,2015,67(2 Pt A):171-182.
[7] Vidarsson G,Dekkers G,Rispens T.IgG subclasses and allotypes:from structure to effector functions.Front Immunol,2014,5(520):1-17.
[8] Liu H,May K.Disulfide bond structures of IgG molecules.MAbs,2012,4(1):17-23.
[9] Tian X S,Langkiled A E,Thorolfsson M.Small-angle X-ray scattering screening complements conventional biophysical analysis:comparative structural and biophysical analysis of monoclonal antibodies IgG1,IgG2,and IgG4.Journal of Pharmaceutical Sciences,2014,103(6):1701-1710.
[10] Pepinsky R B,Silvian L,Berkowitz S A,et al.Improving the solubility of anti-LINGO-1 monoclonal antibody Li33 by isotype switching and targeted mutagenesis.Protein Sci,2010,19(5):954-966.
[11] Thakkar S V,Sahni N,Joshi S B,et al.Understanding the relevance of local conformational stability and dynamics to the aggregation propensity of an IgG1 and IgG2 monoclonal antibodies.Protein Sci,2013,22(10):1295-1305.
[12] Beenhouwer D O,Yoo E M,Lai C W,et al.Human immunoglobulin G2(IgG2) and IgG4,but Not IgG1 or IgG3,Protect mice against cryptococcus neoformans infection.Infect Immun,2007,5(3):1424-1435.
[13] Varshney A K,Wang X,Aguilar J L,et al.Isotype switching increases efficacy of antibody protection against staphylococcal enterotoxin B-induced lethal shock and Staphylococcus aureus sepsis in mice.MBio,2014,5(3):e01007-e01014.
[14] Lee J H,Yeo J,Park H S,et al.Biochemical characterization of a new recombinant TNF receptor-hyFc fusion protein expressed in CHO cells.Protein Expr Purif,2013,87(1):17-26.
[15] K nitzer J D,Sieron A,Wacker A,et al.Reformatting rituximab into human IgG2 and IgG4 isotypes dramatically improves apoptosis induction in vitro.PLoS One,2015,10(12):e0145633.
[16] Correia I R.Stability of IgG isotypes in serum.MAbs,2010,2(3):221-232.
[17] Stapleton N M,Andersen J T,Stemerding A M,et al.Competition for FcRn-mediated transport gives rise to short half-life of human IgG3 and offers therapeutic potential.Nature Communications,2011,2:599-608.
[18] Rispens T,Davies A M,Ooijevaar-de Heer P,et al.Dynamics of inter-heavy chain interactions in human immunoglobulin G (IgG) subclasses studied by kinetic Fab arm exchange.J Biol Chem,2014,289(9):6098-6109.
[19] Labrijn A F,Meesters J I,Priem P,et al.Controlled Fab-arm exchange for the generation of stable bispecific IgG1.Nat Protoc,2014,9(10):2450-2463.
[20] Labrijna A F,Meestersa J I,Bart E C G,et al.Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange.PNAS,2013,110(13):5145-5150.
[21] Gramer M J,van den Bremer E T,van Kampen M D,et al.Production of stable bispecific IgG1 by controlled Fab-arm exchange.MAbs,2013,5(6):962-973.
[22] Tishchenko V M.Correlation between macro-and micro-stability C (H)2 domains of human IGG2 and their biological activity.1.Ansalysis the calorimetric and optical melting curves.Mol Biol (Mosk),2014,48(3):480-490.
[23] Tishchenko V M.Correlation between macro-and micro-stability C (H)2 domains of human IgG2 and their biological activity.Ⅱ.Calculation of thermodynamic functions characterizing domains stability.Mol Biol (Mosk),2014,48(5):842-849.
[24] Aboel Dahab A,El-Hag D.Effective protocol for the investigation of physicochemical and conformational stability and aggregation kinetics measurements of therapeutic IgG2 monoclonal antibody.J Immunol Methods,2014,405:154-166.
[25] Sahin E,Weiss W F 4th,Kroetsch A M,et al.Aggregation and pH-temperature phase behavior for aggregates of an IgG2 antibody.J Pharm Sci,2012,101(5):1678-1687.
[26] White A L,Chan H T C,French R R,et al.Conformation of the human immunoglobulin G2 hinge imparts superagonistic properties to immunostimulatory anticancer antibodies.Cancer Cell,2015,27(1):138-148.
[27] Rispens T,Leeuwen A V,Vennegoor A,et al.Measurement of serum levels of natalizumab,an immunoglobulin G4 therapeutic monoclonal antibody.Anal Biochem,2011,411(2):271-276.
[28] Labrijn A F,Rispens T,Meesters J,et al.Species-specific determinants in the IgG CH3 domain enable Fab-arm exchange by affecting the noncovalent CH3-CH3 interaction strength.J Immunol,2011,187(6):3238-3246.
[29] Labrijn A F,Buijsse A O,van den Bremer E T,et al.Therapeutic IgG4 antibodies engage in Fab-arm exchange with endogenous human IgG4in vivo.Nat Biotechnol,2009,27(8):767-771.
[30] Silva J P,Vetterlein O,Jose J,et al.The S228P mutation prevents in vivo and in vitro IgG4 Fab-arm exchange as demonstrated using a combination of novel quantitative immunoassays and physiological matrix preparation.J Biol Chem,2015,290(9):5462-5469.
[31] Davies A M,Rispens T,Ooijevaar-de Heer P,et al.Structural determinants of unique properties of human IgG4-Fc.Mol Biol,2014,426(3):630-644.
[32] Rispens T,Ooijevaar-de Heer P,Bende O,et al.Mechanism of immunoglobulin G4 Fab-arm exchange.J Am Chem Soc,2011,133(26):10302-10311.
[33] Spiess C,Bevers J,Jackman J,et al.Development of a human IgG4 bispecific antibody for dual targeting of interleukin-4(IL-4) and interleukin-13(IL-13) cytokines.Biol Chem,2013,288(37):26583-26593.
[34] Korde N,Carlsten M,Lee M J,et al.A phase Ⅱ trial of pan-KIR2D blockade with IPH2101 in smoldering multiple myeloma.Haematologica,2014,99(6):81-83. |
